COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02157103
Recruitment Status : Completed
First Posted : June 5, 2014
Results First Posted : April 13, 2018
Last Update Posted : May 17, 2018
Information provided by (Responsible Party):
William Read, Emory University

Brief Summary:


This research will involve patients with glioblastoma. The drug bevacizumab (Avastin) is FDA approved for the treatment of glioblastoma that gets worse after standard therapy. For glioblastoma, bevacizumab is given by vein every 14 days. The purpose of this study is to see if bevacizumab works as well when it is given as a daily subcutaneous shot as it does when given intravenously. A subcutaneous shot is like an insulin shot or a heparin shot. The dose of bevacizumab given on this study is in total slightly lower than the FDA approved dose for glioblastoma.


About 10 people will take part in the study. Participants or caregivers will be educated on injection and given prefilled syringes to take home. Participants or caregivers will administer bevacizumab subcutaneously each day. The bevacizumab will be stored in the refrigerator.

Follow up visits will be weekly for the first 3 weeks, then every 3 weeks. After 18 weeks, the follow up interval can be increased to every 6 weeks at the treating physician's discretion.

Participants can keep taking the bevacizumab until:

  • Tests show that they are not benefiting from it,
  • The participant has a bad side effect related to study treatment,
  • The participant can no longer comply with study requirements, or
  • The participant or doctor feels it is no longer in the participant's best interest.

Condition or disease Intervention/treatment Phase
Glioblastoma Drug: Bevacizumab 25 mg in 1 ml subcutaneously daily Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma
Actual Study Start Date : January 2014
Actual Primary Completion Date : November 2016
Actual Study Completion Date : January 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema
Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Bevacizumab
Cycle 1 (each cycle is 3 weeks): Bevacizumab 25 mg in 1 ml subcutaneously daily.
Drug: Bevacizumab 25 mg in 1 ml subcutaneously daily
Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
Other Name: Avastin

Primary Outcome Measures :
  1. Number of Participants With Change in Peritumoral Enhancement/Edema [ Time Frame: 1 cycle (3 weeks) ]
    To describe MRI response regarding edema and enhancement of glioblastoma and radiation-related brain enhancement when treated with subcutaneous bevacizumab daily. The therapeutic benefit of bevacizumab as regards glioblastoma multiforme (GBM) is largely due to the normalization of brain vasculature. This normalization appears on contrast-enhanced MRI as a reduction in enhancement and reduction in edema. For purposes of this study, any reduction in enhancement/edema by 25% or more will be considered a response.

Secondary Outcome Measures :
  1. Number of Toxicities Reported in Study Participants [ Time Frame: During first 3 weeks of study ]
    Subcutaneous bevacizumab may have toxicities unique to the subcutaneous administration and not seen with intravenous bevacizumab. During the first 3 weeks we will watch for such toxicities. Toxicities will be described and graded using the Common Toxicity Criteria for Adverse Effects (CTCAE) v3.

  2. Number of Participants With Change in Edema After Conversion From Study Treatment to Intravenous Bevacizumab [ Time Frame: Within 2 months of starting intravenous bevacizumab ]
    Participants may switch from subcutaneous bevacizumab on study to standard of care intravenous bevacizumab. In these participants, we will measure decrease of edema after this switch. A further decrease in edema after making this switch would suggest intravenous to be superior to subcutaneous as regards decreasing edema. The therapeutic benefit of bevacizumab as regards GBM is largely due to the normalization of brain vasculature. This normalization appears on contrast-enhanced MRI as a reduction in edema. For purposes of this study, any reduction in edema by 25% or more will be considered a response.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis: Participants with glioblastoma are eligible for this study. These will include

    • Those with a histologically proven diagnosis of glioblastoma who have developed new changes on MRI following primary treatment.
    • Those who received primary treatment for a histologically proven lower grade (2 or 3) glioma and who now progress with radiographic characteristics of transformed glioma.
  • Disease status: Patients must have abnormal enhancement on contrast enhanced MRI of the brain. They must be patients for whom bevacizumab is indicated and appropriate, as drug will be charged to insurance.

    • Participants with newly detected enhancement are eligible, with bevacizumab treatment hoped to prevent symptoms.
    • Participants with stable enhancement / edema are eligible if they require corticosteroids to control symptoms, and it is thought bevacizumab treatment might allow lowering of the corticosteroid dose or improvement of symptoms.
  • Performance status: Eastern Cooperative Oncology Group (ECOG) 0-3.
  • Age: Greater than 18 years.
  • Life expectancy: > 3 months.
  • Prior therapy:

    • Anti-VEGF treatments: 3 months must have elapsed between any prior anti-VEGF treatment (for example, given as a component of primary treatment) and study participation. These therapies include bevacizumab, cediranib, axitinib, sunitinib as well as other therapeutics targeting VEGF.
    • Other anti-cancer treatments: Treatments in this category include chemotherapy and targeted therapies not targeting VEGF. 14 days must have elapsed since discontinuation of prior chemotherapeutic treatments for glioma and study treatment.
  • Radiation: Radiation is integral to the primary treatment of glioma. All participants on this study must have had prior radiation to the brain. Radiation must have been completed 14 days prior to first study treatment.
  • Surgery: 14 days must have elapsed since prior major surgery.
  • Organ function requirements:

    • Creatinine clearance of 50 or greater.
    • Absolute neutrophil count of 1500 or greater.
  • Blood pressure requirements: Participants must have a baseline blood pressure of 160/90 or less. Participants requiring medicines to control blood pressure are eligible.
  • Informed consent: All patients must sign a written informed consent.
  • Urine pregnancy test: Women of childbearing age must have a negative urine pregnancy test.

Exclusion Criteria:

  • People who progress with only nonenhancing tumor on MRI are ineligible. Patients must have some component of abnormal enhancement on contrast enhanced MRI of the brain. Combinations of nonenhancing and enhancing tumor are eligible.
  • Pregnancy or breast-feeding: Pregnant or breast-feeding women will not be entered on this study.
  • Renal insufficiency: Patients with a creatinine clearance of less than 50 are ineligible.
  • Proteinuria: Patients with 2+ proteinuria/Moderate or more at baseline are ineligible.
  • Comorbidities: Patients may not have any baseline comorbidities or laboratory abnormalities which would be of grade 3 or worse if graded as toxicities by CTCAE (excepting alopecia). An exception is also made for neurologic comorbidities (eg ataxia, aphasia) arising as a consequence of the brain tumor; symptoms severe enough to warrant medical treatment as is offered on this study are by definition grade 3.
  • Patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.
  • Illness or any other circumstances (as defined by the investigator), which would preclude safe performance of study procedures or compromise the ability of the patient to consent to study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02157103

Layout table for location information
United States, Georgia
Emory University Hospital Midtown
Atlanta, Georgia, United States, 30308
Emory University Winship Cancer Institutute
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Layout table for investigator information
Principal Investigator: William L. Read, MD Emory University
Layout table for additonal information
Responsible Party: William Read, Principal Investigator, Emory University Identifier: NCT02157103    
Other Study ID Numbers: IRB00062998
Winship2299-12 ( Other Identifier: Winship Cancer Institute )
First Posted: June 5, 2014    Key Record Dates
Results First Posted: April 13, 2018
Last Update Posted: May 17, 2018
Last Verified: April 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Keywords provided by William Read, Emory University:
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors